Doximity Resultados de beneficios anteriores

Pasado controles de criterios 5/6

Doximity ha aumentado sus beneficios a una tasa media anual de 34.4%, mientras que los beneficios de la industria de Healthcare Services han experimentado un crecimiento de 15.2% anual. Los ingresos han ido creciendo a una tasa media de 24% al año. La rentabilidad financiera de Doximity es de 19.5%, y sus márgenes netos son de 36.6%.

Información clave

34.4%

Tasa de crecimiento de los beneficios

23.5%

Tasa de crecimiento del BPA

Crecimiento de la industria Healthcare Services	1.7%
Tasa de crecimiento de los ingresos	24.0%
Rentabilidad financiera	19.5%
Margen neto	36.6%
Próxima actualización de resultados	15 May 2025

Actualizaciones de resultados anteriores recientes

Recent updates

Earnings Not Telling The Story For Doximity, Inc. (NYSE:DOCS) After Shares Rise 34%

Nov 13

Does This Valuation Of Doximity, Inc. (NYSE:DOCS) Imply Investors Are Overpaying?

Nov 02

Is Doximity, Inc. (NYSE:DOCS) Potentially Undervalued?

Oct 15

Doximity: Downgrade To Hold On Valuation Concerns

Oct 03

Here's Why Doximity (NYSE:DOCS) Has Caught The Eye Of Investors

Sep 23

Generative AI And Digital Health Innovations Fuel Robust Revenue Growth And Market Expansion

Aug 28 Accelerating adoption of new products and a client portal, alongside strategic positioning with top clients, suggests sustained revenue expansion.

There's Reason For Concern Over Doximity, Inc.'s (NYSE:DOCS) Massive 27% Price Jump

Aug 18

Doximity (NYSE:DOCS) Looks To Prolong Its Impressive Returns

Aug 10

Doximity Faces Slower Revenue Growth As R&D Costs May Rise

Jul 23

Is Doximity, Inc. (NYSE:DOCS) Trading At A 23% Discount?

Jul 23

At US$27.97, Is It Time To Put Doximity, Inc. (NYSE:DOCS) On Your Watch List?

Jul 01

Optimistic Investors Push Doximity, Inc. (NYSE:DOCS) Shares Up 26% But Growth Is Lacking

Jun 09

Doximity Earnings: Better Than Expected, But Still Mixed Outlook (Rating Upgrade)

May 17

Capital Allocation Trends At Doximity (NYSE:DOCS) Aren't Ideal

May 04

Doximity: Significant Upside Remains, But Not Until The Growth Story Returns

Apr 29

Doximity: Rating Upgrade To Buy As Outlook Turns Positive

Feb 21

Doximity: Downside Is Contained, While Upside Depends On Management's Game Plan

Jan 16

Doximity Earnings: Steer Clear Of This Rollercoaster War Of Optimism Vs. Skepticism

Nov 10

Doximity: Adding Value Using AI But Faces Near-Term Risks

Nov 01

Doximity: Rating Downgrade As Investors Shift Focus To The Near-Term Outlook

Aug 24

Doximity Earnings: Too Many Problems, Sell

Aug 09

Doximity: Continue To See Positive Upside From Current Stock Level

Jul 05

Desglose de ingresos y gastos

Cómo gana y gasta dinero Doximity. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NYSE:DOCS Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Dec 24	550	201	184	88
30 Sep 24	517	174	176	86
30 Jun 24	494	161	171	83
31 Mar 24	475	148	170	82
31 Dec 23	468	138	169	83
30 Sep 23	448	123	167	84
30 Jun 23	437	119	166	83
31 Mar 23	419	113	160	80
31 Dec 22	402	119	153	76
30 Sep 22	384	141	146	72
30 Jun 22	362	148	138	68
31 Mar 22	344	133	128	62
31 Dec 21	317	107	114	57
30 Sep 21	277	57	101	53
30 Jun 21	243	30	88	47
31 Mar 21	207	22	78	44
31 Dec 20	177	14	67	40
31 Mar 20	116	11	46	32
31 Mar 19	86	1	40	27

Ingresos de calidad: DOCS tiene ganancias de alta calidad.

Margen de beneficios creciente: Los actuales márgenes de beneficio (36.6%) de DOCS son superiores a los del año pasado (29.4%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: En los últimos 5 años, los beneficios de lDOCS han crecido significativamente en un 34.4% al año.

Acelerando crecimiento: El crecimiento de los beneficios de DOCS en el último año (46.3%) supera su media de 5 años (34.4% al año).

Beneficios vs. Industria: El crecimiento de los beneficios de DOCS en el último año (46.3%) superó al de la industria Healthcare Services 31.5%.

Rentabilidad financiera

Alta ROE: La rentabilidad financiera de DOCS (19.5%) se considera baja.

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado

Análisis de la empresa y estado de los datos financieros

Datos	Última actualización (huso horario UTC)
Análisis de la empresa	2025/04/27 00:22
Precio de las acciones al final del día	2025/04/25 00:00
Beneficios	2024/12/31
Ingresos anuales	2024/03/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

Paquete	Datos	Marco temporal	Ejemplo Fuente EE.UU. ^*
Finanzas de la empresa	10 años	Cuenta de resultados Estado de tesorería Balance	Formulario SEC 10-K Formulario SEC 10-Q
Estimaciones del consenso de analistas	+3 años	Previsiones financieras Objetivos de precios de los analistas	Informes de análisis Blue Matrix
Precios de mercado	30 años	Precios de las acciones Dividendos, escisiones y acciones	Datos de mercado ICE Formulario S-1 de la SEC
Propiedad	10 años	Accionistas principales Información privilegiada	Formulario SEC 4 Formulario SEC 13D
Gestión	10 años	Equipo directivo Consejo de Administración	Formulario SEC 10-K Formulario SEC DEF 14A
Principales avances	10 años	Anuncios de empresas	Formulario SEC 8-K

^* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Doximity, Inc. está cubierta por 27 analistas. 19 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

Analista	Institución
Vikram Kesavabhotla	Baird
Nisala Weerasuriya	Berenberg
Allen Lutz	BofA Global Research

Doximity Resultados de beneficios anteriores

Pasado controles de criterios 5/6

Información clave

Actualizaciones de resultados anteriores recientes

Doximity, Inc. to Report Q4, 2025 Results on May 15, 2025

Doximity, Inc. to Report Q3, 2025 Results on Feb 06, 2025

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Doximity, Inc. to Report Q2, 2025 Results on Nov 07, 2024

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Doximity, Inc. to Report Q1, 2025 Results on Aug 08, 2024

Recent updates

Doximity, Inc. to Report Q4, 2025 Results on May 15, 2025

Shareholders Are Optimistic That Doximity (NYSE:DOCS) Will Multiply In Value

What Doximity, Inc.'s (NYSE:DOCS) 28% Share Price Gain Is Not Telling You

Co-Founder recently sold US$62m worth of stock

Investor sentiment improves as stock rises 29%

Doximity Q3 Earnings: Outpacing Even Management's Expectations

Price target increased by 27% to US$70.06

Now 24% overvalued after recent price rise

Doximity, Inc. Provides Earnings Guidance for the Fiscal Fourth Quarter Ending March 31, 2025 and Updates Earnings Guidance for the Fiscal Year Ending March 31, 2025

Independent Director notifies of intention to sell stock

When Should You Buy Doximity, Inc. (NYSE:DOCS)?

Doximity, Inc. to Report Q3, 2025 Results on Feb 06, 2025

Now 21% overvalued after recent price rise

Doximity: Upgraded To Buy Amid Promising Growth And Strong Execution

Here's Why We Think Doximity (NYSE:DOCS) Is Well Worth Watching

Now 24% overvalued after recent price rise

Doximity: Strong Fundamentals And Growth Potential Makes It Attractive

Doximity (NYSE:DOCS) Knows How To Allocate Capital

Investor sentiment improves as stock rises 20%

Chief Financial Officer notifies of intention to sell stock

Earnings Not Telling The Story For Doximity, Inc. (NYSE:DOCS) After Shares Rise 34%

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Doximity, Inc. Provides Earnings Guidance for Its Fiscal Third Quarter Ending December 31, 2024 and Updating Earnings Guidance for Its Fiscal Year Ending March 31, 2025

Independent Director notifies of intention to sell stock

Does This Valuation Of Doximity, Inc. (NYSE:DOCS) Imply Investors Are Overpaying?

Doximity, Inc. to Report Q2, 2025 Results on Nov 07, 2024

Price target increased by 8.5% to US$37.21

Is Doximity, Inc. (NYSE:DOCS) Potentially Undervalued?

Doximity: Downgrade To Hold On Valuation Concerns

Here's Why Doximity (NYSE:DOCS) Has Caught The Eye Of Investors

Now 22% overvalued after recent price rise

Generative AI And Digital Health Innovations Fuel Robust Revenue Growth And Market Expansion

There's Reason For Concern Over Doximity, Inc.'s (NYSE:DOCS) Massive 27% Price Jump

Investor sentiment improves as stock rises 39%

Chief Financial Officer exercised options and sold US$1.1m worth of stock

Price target increased by 7.1% to US$31.64

Doximity (NYSE:DOCS) Looks To Prolong Its Impressive Returns

New minor risk - Share price stability

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Doximity, Inc. Provides Revenue Guidance for the Second Quarter Ending September 30, 2024 and Fiscal Year Ending March 31, 2025

Doximity Faces Slower Revenue Growth As R&D Costs May Rise

Is Doximity, Inc. (NYSE:DOCS) Trading At A 23% Discount?

Doximity, Inc., Annual General Meeting, Aug 29, 2024

Doximity, Inc. to Report Q1, 2025 Results on Aug 08, 2024

Now 29% undervalued

Now 28% undervalued

At US$27.97, Is It Time To Put Doximity, Inc. (NYSE:DOCS) On Your Watch List?

Now 22% undervalued after recent price drop

Chief Financial Officer notifies of intention to sell stock

Optimistic Investors Push Doximity, Inc. (NYSE:DOCS) Shares Up 26% But Growth Is Lacking

Investor sentiment improves as stock rises 18%

Doximity, Inc. Provides Financial Guidance for the First Quarter Ending June 30, 2024 and Full Year Ending March 31, 2025

Full year 2024 earnings released: EPS: US$0.78 (vs US$0.58 in FY 2023)

Doximity Earnings: Better Than Expected, But Still Mixed Outlook (Rating Upgrade)

Doximity, Inc. (NYSE:DOCS) announces an Equity Buyback for $500 million worth of its shares.

Capital Allocation Trends At Doximity (NYSE:DOCS) Aren't Ideal

Doximity: Significant Upside Remains, But Not Until The Growth Story Returns

Doximity, Inc. to Report Q4, 2024 Results on May 16, 2024

Kessler Topaz Meltzer & Check, LLP Files Securities Fraud Class Action Lawsuit Against Doximity, Inc

Doximity: Rating Upgrade To Buy As Outlook Turns Positive

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Doximity, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ending March 31, 2024

Price target increased by 7.2% to US$28.17

Doximity, Inc. to Report Q3, 2024 Results on Feb 08, 2024

Doximity: Downside Is Contained, While Upside Depends On Management's Game Plan

Now 21% undervalued

Investor sentiment improves as stock rises 24%

Doximity, Inc. Provides Revenue Guidance for the Fiscal Third Quarter Ending December 31, 2023 and Fiscal Year Ending March 31, 2024

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations